76 related articles for article (PubMed ID: 30296409)
21. PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes.
Zhang F; Sun J; Zhang L; Li R; Wang Y; Geng H; Shen C; Li L; Chen L
Br J Cancer; 2024 May; ():. PubMed ID: 38806724
[TBL] [Abstract][Full Text] [Related]
22. Regulation of transcription patterns, poly-ADP-ribose, and RNA-DNA hybrids by the ATM protein kinase.
Woolley PR; Wen X; Conway OM; Ender NA; Lee JH; Paull TT
bioRxiv; 2023 Dec; ():. PubMed ID: 38106035
[TBL] [Abstract][Full Text] [Related]
23. Myocardial AKT: the omnipresent nexus.
Sussman MA; Völkers M; Fischer K; Bailey B; Cottage CT; Din S; Gude N; Avitabile D; Alvarez R; Sundararaman B; Quijada P; Mason M; Konstandin MH; Malhowski A; Cheng Z; Khan M; McGregor M
Physiol Rev; 2011 Jul; 91(3):1023-70. PubMed ID: 21742795
[TBL] [Abstract][Full Text] [Related]
24. Melatonin derivative 6a as a PARP-1 inhibitor for the treatment of Parkinson's disease.
Ma QW; Han RT; Wu ZJ; Zhou JJ; Chen MT; Zhang XZ; Ma WZ; Feng N
Front Pharmacol; 2024; 15():1363212. PubMed ID: 38476326
[TBL] [Abstract][Full Text] [Related]
25. Converting cell death into senescence by PARP1 inhibition improves recovery from acute oxidative injury.
Nehme J; Mesilmany L; Varela-Eirin M; Brandenburg S; Altulea A; Lin Y; Gaya da Costa M; Seelen M; Hillebrands JL; van Goor H; Saab R; Akl H; Prevarskaya N; Farfariello V; Demaria M
Nat Aging; 2024 May; ():. PubMed ID: 38724734
[TBL] [Abstract][Full Text] [Related]
26. Mitochondrial Protection by PARP Inhibition.
Gallyas F; Sumegi B
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316192
[TBL] [Abstract][Full Text] [Related]
27. Poly(ADP-Ribose) Polymerases-Inhibitor Talazoparib Inhibits Muscle Atrophy and Fatty Infiltration in a Tendon Release Infraspinatus Sheep Model: A Pilot Study.
Olthof MGL; Hasler A; Valdivieso P; Flück M; Gerber C; Gehrke R; Klein K; von Rechenberg B; Snedeker JG; Wieser K
Metabolites; 2024 Mar; 14(4):. PubMed ID: 38668315
[TBL] [Abstract][Full Text] [Related]
28. A gain-of-function mutation in microRNA 142 is sufficient to cause the development of T-cell leukemia in mice.
Kawano S; Araki K; Bai J; Furukawa I; Tateishi K; Yoshinobu K; Usuki S; Nimmo RA; Kaname T; Yoshihara M; Takahashi S; Sashida G; Araki M
Cancer Sci; 2023 Jul; 114(7):2821-2834. PubMed ID: 36945113
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial metabolism: a predictive biomarker of radiotherapy efficacy and toxicity.
Taghizadeh-Hesary F; Houshyari M; Farhadi M
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6719-6741. PubMed ID: 36719474
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Clinically Used PARP Inhibitors in a Murine Model of Acute Lung Injury.
Martins V; Santos SS; Rodrigues LOCP; Salomao R; Liaudet L; Szabo C
Cells; 2022 Nov; 11(23):. PubMed ID: 36497049
[TBL] [Abstract][Full Text] [Related]
31. Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
Franzese O; Graziani G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428727
[TBL] [Abstract][Full Text] [Related]
32. Using Patient-Derived Xenograft (PDX) Models as a 'Black Box' to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial.
Chen J; Li Y; Wang H; Li T; Gu Y; Wang W; Shan Y; Yin J; Wang Y; Qin M; Li S; Pan L; Peng S; Jin Y
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230574
[TBL] [Abstract][Full Text] [Related]
33. KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib
Jiang L; Liu Y; Su X; Wang J; Zhao Y; Tumbath S; Kilgore JA; Williams NS; Chen Y; Wang X; Mendonca MS; Lu T; Fu YX; Huang X
Front Oncol; 2022; 12():976292. PubMed ID: 36203459
[TBL] [Abstract][Full Text] [Related]
34. RPRM negatively regulates ATM levels through its nuclear translocation on irradiation mediated by CDK4/6 and IPO11.
Zhang Y; Ou G; Ye Z; Zhou Z; Cao Q; Li M; Wang J; Cao J; Yang H
iScience; 2022 Oct; 25(10):105115. PubMed ID: 36185355
[TBL] [Abstract][Full Text] [Related]
35. Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD
Li J; Koczor CA; Saville KM; Hayat F; Beiser A; McClellan S; Migaud ME; Sobol RW
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892832
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.
Zhang X; Huang P; Wang L; Chen S; Basappa B; Zhu T; Lobie PE; Pandey V
Cell Death Dis; 2022 Jun; 13(6):558. PubMed ID: 35725817
[TBL] [Abstract][Full Text] [Related]
37. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
Tiwari P; Khan H; Singh TG; Grewal AK
Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
[TBL] [Abstract][Full Text] [Related]
38. Mammalian AKT, the Emerging Roles on Mitochondrial Function in Diseases.
Xie X; Shu R; Yu C; Fu Z; Li Z
Aging Dis; 2022 Feb; 13(1):157-174. PubMed ID: 35111368
[TBL] [Abstract][Full Text] [Related]
39. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Perez JM; Twigg CAI; Guan W; Thomas SN
J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
[TBL] [Abstract][Full Text] [Related]
40. Interplay between ADP-ribosyltransferases and essential cell signaling pathways controls cellular responses.
Cell Discov; ; . PubMed ID: 34725336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
